Are Oils-Energy Stocks Lagging Calumet, Inc. (CLMT) This Year?

Calumet (CLMT) has gained 148.2% year to date, ahead of the Oils-Energy sector’s 36.5% return and its industry group’s 42% average. Its Zacks consensus full-year earnings estimate rose 1,110.5% over the past 90 days, and the stock carries a Zacks Rank #2 (Buy). ConocoPhillips gained 55.6% year to date, while its current-year consensus EPS estimate increased 21.6% over the past three months.

Analysis

Signal quality: low-to-moderate. The revision headline is not a reliable measure of incremental earnings power: an 1,110% change can result from a very small starting estimate. Before treating it as fundamental confirmation, verify the absolute EPS level, the number and breadth of estimate changes, and whether earnings translate into operating cash flow. The large year-to-date rerating also raises the bar for further upside; estimate momentum may already be reflected in price.

The peer comparison is economically weak. Calumet’s refining and specialty-products exposures are not interchangeable with ConocoPhillips’ upstream earnings drivers, so COP is not a clean hedge for crude-price risk. For Calumet, monitor feedstock/product spreads, utilization, and any segment-level guidance; for COP, crude and natural-gas prices matter more directly.

Horizon: Near term, trend-following flows could sustain CLMT, making an immediate outright short vulnerable. Over 1–3 months, the key catalyst is whether reported results validate revisions in absolute earnings and cash generation. Over 6–18 months, operating performance and commodity-cycle exposure should matter more than rank-based momentum. The bullish case weakens if estimate revisions reverse, results miss the revised outlook, or relevant product spreads deteriorate. The article supplies no valuation, earnings base, or operating data to establish fair value.

Key Decisions for Investors

• Do not chase CLMT solely on the rank or percentage revision. Verify absolute consensus EPS, estimate breadth, segment results, and cash conversion at the next earnings update before adding exposure.
• For a relative-value expression, consider a small, risk-limited CLMT underweight versus COP only if the thesis is Calumet-specific earnings expectations becoming too optimistic—not as a crude hedge. Define risk by the spread and reassess if Calumet delivers sustained cash-flow improvement; check borrow and options liquidity first.
• Watch for confirmation over the next 1–3 months: upward revisions supported by reported operating results and cash generation would argue against fading the rally; downward revisions, weaker relevant spreads, or a guidance miss would support reducing exposure.